What are iRadimed's total assets?

iRadimed (IRMD) holds $114.4M in total assets, up 12.4% year over year.

How much cash does iRadimed have?

iRadimed holds $56.4M in cash and equivalents.

Can iRadimed cover its short-term obligations?

Its current ratio is 7.13 — current assets exceed current liabilities.

Where does iRadimed's balance sheet data come from?

Every line is extracted from iRadimed's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

iRadimed IRMD Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$51.16M-2.1%	$52.23M+5.0%	$49.76M-14.1%	$57.96M-6.5%
Accounts receivable, net	$13.67M+29.5%	$10.56M-13.6%	$12.22M-7.9%	$13.27M+158%
Inventories	$12.18M+17.0%	$10.4M-18.9%	$12.82M+139%	$5.37M+24.9%
Raw materials	$9.61M—	——	——	——
Work in process	$831K—	——	——	——
Finished goods	$1.73M—	——	——	——
Prepaid expenses and other current assets	$1.65M-19.7%	$2.05M+71.8%	$1.19M+89.1%	$630.96K-36.9%
Income taxes receivable	$3.11M+480%	$536.01K—	——	$254.09K-92.3%
Total current assets	$81.2M+7.9%	$75.24M-1.0%	$76M-1.9%	$77.49M+1.6%
Property and equipment, net	$23.86M+41.9%	$16.81M+81.0%	$9.29M+287%	$2.4M+16.0%
Accumulated depreciation	$5.07M—	——	——	——
Intangible assets, net	$3.38M+9.2%	$3.1M+23.0%	$2.52M+21.7%	$2.07M+85.0%
Deferred tax assets	$94K-96.7%	$2.82M+32.8%	$2.12M+203%	$700.87K-8.4%
Other non-current assets	$239K-32.5%	$354K+95.1%	$181.45K-72.0%	$648.67K+222%
Total assets	$108.78M+10.6%	$98.33M+6.7%	$92.16M+7.8%	$85.51M+3.2%
Accounts payable	$1.82M-4.0%	$1.9M+2.1%	$1.86M+3.2%	$1.8M+130%
Accrued expenses	$3.22M-14.7%	$3.77M+35.9%	$2.78M-3.4%	$2.87M+2.0%
Deferred revenue	$2.87M+27.0%	$2.26M-12.1%	$2.57M-23.8%	$3.37M+32.1%
Contract liabilities	$3.98M+32.9%	$2.99M+7.1%	$2.79M+103%	$1.38M-18.1%
Income taxes payable	——	$338.75K—	——	$3.34M+482%
Total current liabilities	$10.18M+19.6%	$8.51M-47.9%	$16.33M+90.9%	$8.55M+25.4%
Total liabilities	$14.16M+23.0%	$11.51M-44.5%	$20.74M+75.1%	$11.84M+10.6%
Common stock	31.5M+3,149,900%	1K-20.9%	1.3K+0.5%	1.3K+0.4%
Additional paid-in capital	$30.39M+1.2%	$30.03M+6.6%	$28.16M+6.6%	$26.41M+5.0%
Retained earnings	$64.23M+13.1%	$56.79M+31.3%	$43.26M-8.5%	$47.26M+0.6%
Total stockholders' equity	$94.62M+9.0%	$86.82M+21.6%	$71.42M-3.1%	$73.67M+2.1%
Total liabilities and stockholders' equity	$108.78M+10.6%	$98.33M+6.7%	$92.16M+7.8%	$85.51M+3.2%
Allowance for Doubtful Accounts	$191K—	——	——	——
Allowance for Doubtful Accounts Receivable (Current)	$191K—	——	——	——
Inventory Valuation Adjustments	$555K—	——	——	——
Capitalized Contract Costs, Net	$239K—	——	——	——
Deferred Tax Assets and Other Non-Current Assets	$239K-32.5%	$354K+95.1%	$181.45K-72.0%	$648.67K+222%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Finite-Lived Intangible Assets - Expected Amortization Expense (Year Five)	——	——	——	——
Finite Lived Intangible Assets - Gross	$4.94M—	——	——	——
Deferred tax assets	$94K-96.7%	$2.82M+32.8%	$2.12M+203%	$700.87K-8.4%
Intangible assets — net	$3.38M+9.2%	$3.1M+23.0%	$2.52M+21.7%	$2.07M+85.0%
Other non-current assets	$239K-32.5%	$354K+95.1%	$181.45K-72.0%	$648.67K+222%
Property, plant and equipment at cost	$28.93M—	——	——	——
Software and Technology Licenses, Net	$239K-32.5%	$354K+95.1%	$181.45K-72.0%	$648.67K+222%
Accrued Manufacturing Costs	$3.22M-14.7%	$3.77M+35.9%	$2.78M-3.4%	$2.87M+2.0%
Accrued Progress Collections and Price Adjustments	$3.98M+32.9%	$2.99M+7.1%	$2.79M+103%	$1.38M-18.1%
Accrued Income Taxes, Current	$1.81M—	——	$250.04K—	——
Compensation and benefits	$3.22M-14.7%	$3.77M+35.9%	$2.78M-3.4%	$2.87M+2.0%
Current portion of accrued product warranty	$144K+22.0%	$118K+0.5%	$117.46K+24.9%	$94.03K-13.6%
Standard Product Warranty Accrual	$144K+22.0%	$118K+0.5%	$117.46K+24.9%	$94.03K-13.6%
Contract Liabilities, Non-Current	$3.98M+32.9%	$2.99M+7.1%	$2.79M+103%	$1.38M-18.1%
Deferred revenue, net of current portion	$3.98M+32.9%	$2.99M+7.1%	$2.79M+103%	$1.38M-18.1%
Common Stock Par Value Per Share	$0.00—	——	——	——
Common Stock Shares Issued	12.8M—	——	——	——
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$1K0.0%	$1K-20.9%	$1.27K+0.5%	$1.26K+0.4%
Cumulative Cost Basis	$28.93M—	——	——	——
Advance payments from customers	$486K—	——	——	——
Allowance for doubtful accounts	$191K—	——	——	——
Capitalized Contract Cost, Net	$239K—	——	——	——
Common stock, par value (in dollars per share)	$0—	——	——	——
Common stock, shares authorized (in shares)	$31.5M—	——	——	——
Common stock, shares issued (in shares)	$12.78M—	——	——	——
Common Stock, Shares, Outstanding	$12.78M—	——	——	——
Contract with Customer, Liability	$6.85M+30.4%	$5.25M—	——	——
Extended maintenance agreements	$6.27M—	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$1.56M—	——	——	——
2028	——	——	——	——
2030	——	——	——	——
2031	——	——	——	——
Remainder of 2026	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Finite Lived Intangible Assets Amortization Expense After Year Five	——	——	——	——
Gross Carrying Amount	$4.94M—	——	——	——
Raw materials	$9.61M—	——	——	——
Purchase Obligation	$9.83M—	——	——	——
Shipments in-transit	$93K—	——	——	——
Purchase Obligation	$9.83M—	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about iRadimed.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are iRadimed's total assets?: iRadimed (IRMD) holds $114.4M in total assets, up 12.4% year over year.
How much cash does iRadimed have?: iRadimed holds $56.4M in cash and equivalents.
Can iRadimed cover its short-term obligations?: Its current ratio is 7.13 — current assets exceed current liabilities.
Where does iRadimed's balance sheet data come from?: Every line is extracted from iRadimed's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.